Insilico, Lilly Sign $2.75B AI Drug Discovery Deal
Hong Kong | March 30, 2026 Strategic AI Collaboration to Accelerate Drug Discovery Insilico Medicine has announced a major...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Hong Kong | March 30, 2026 Strategic AI Collaboration to Accelerate Drug Discovery Insilico Medicine has announced a major...
Hong Kong | March 30, 2026 AI Collaboration Accelerates CNS Drug Discovery Insilico Medicine and Tenacia Biotechnology have announced...
March 3, 2026 Insilico Medicine, a clinical-stage biotechnology company known for its generative artificial intelligence platforms, has launched a...
